Literature DB >> 28833936

Persistent C4d and antibody-mediated rejection in pediatric renal transplant patients.

Andrew M South1,2, Lynn Maestretti3, Neeraja Kambham4, Paul C Grimm5, Abanti Chaudhuri5.   

Abstract

Pediatric renal transplant recipient survival continues to improve, but ABMR remains a significant contributor to graft loss. ABMR prognostic factors to guide treatment are lacking. C4d staining on biopsies, diagnostic of ABMR, is associated with graft failure. Persistent C4d+ on follow-up biopsies has unknown significance, but could be associated with worse outcomes. We evaluated a retrospective cohort of 17 pediatric renal transplant patients diagnosed with ABMR. Primary outcome at 12 months was a composite of ≥50% reduction in eGFR, transplant glomerulopathy, or graft failure. Secondary outcome was the UPCR at 12 months. We used logistic and linear regression modeling to determine whether persistent C4d+ on follow-up biopsy was associated with the outcomes. Forty-one percent reached the primary outcome at 12 months. Persistent C4d+ on follow-up biopsy occurred in 41% and was not significantly associated with the primary outcome, but was significantly associated with the secondary outcome (estimate 0.22, 95% CI 0.19-0.25, P < .001), after controlling for confounding factors. Persistent C4d+ on follow-up biopsies was associated with a higher UPCR at 12 months. Patients who remain C4d+ on follow-up biopsy may benefit from more aggressive or prolonged ABMR treatment.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  C1q; donor-specific antibody; graft failure; humoral rejection; proteinuria; transplant glomerulopathy

Mesh:

Substances:

Year:  2017        PMID: 28833936      PMCID: PMC5645786          DOI: 10.1111/petr.13035

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  34 in total

1.  Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts.

Authors:  S R Lederer; B Kluth-Pepper; H Schneeberger; E Albert; W Land; H E Feucht
Journal:  Kidney Int       Date:  2001-01       Impact factor: 10.612

2.  A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation.

Authors:  V Zarkhin; L Li; N Kambham; T Sigdel; O Salvatierra; M M Sarwal
Journal:  Am J Transplant       Date:  2008-09-18       Impact factor: 8.086

3.  Use of single voided urine samples to estimate quantitative proteinuria.

Authors:  J M Ginsberg; B S Chang; R A Matarese; S Garella
Journal:  N Engl J Med       Date:  1983-12-22       Impact factor: 91.245

4.  Glomerular c4d immunoreactivity in acute rejection biopsies of renal transplant patients.

Authors:  M Valente; L Furian; M Della Barbera; C Silvestre; S Marino; M Seveso; E Cozzi; P Rigotti; F B Aiello
Journal:  Transplant Proc       Date:  2012-09       Impact factor: 1.066

5.  Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss.

Authors:  Scott M Sutherland; Ge Chen; Flavia A Sequeira; Calvin D Lou; Steven R Alexander; Dolly B Tyan
Journal:  Pediatr Transplant       Date:  2011-11-17

6.  Summary of FDA antibody-mediated rejection workshop.

Authors:  P Archdeacon; M Chan; C Neuland; E Velidedeoglu; J Meyer; L Tracy; M Cavaille-Coll; S Bala; A Hernandez; R Albrecht
Journal:  Am J Transplant       Date:  2011-05       Impact factor: 8.086

7.  Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.

Authors:  G Einecke; B Sis; J Reeve; M Mengel; P M Campbell; L G Hidalgo; B Kaplan; P F Halloran
Journal:  Am J Transplant       Date:  2009-11       Impact factor: 8.086

8.  Complement-binding anti-HLA antibodies and kidney-allograft survival.

Authors:  Alexandre Loupy; Carmen Lefaucheur; Dewi Vernerey; Christof Prugger; Jean-Paul Duong van Huyen; Nuala Mooney; Caroline Suberbielle; Véronique Frémeaux-Bacchi; Arnaud Méjean; François Desgrandchamps; Dany Anglicheau; Dominique Nochy; Dominique Charron; Jean-Philippe Empana; Michel Delahousse; Christophe Legendre; Denis Glotz; Gary S Hill; Adriana Zeevi; Xavier Jouven
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

Review 9.  The spectrum of antibody-mediated renal allograft injury: implications for treatment.

Authors:  J Gloor; F Cosio; D J Lager; M D Stegall
Journal:  Am J Transplant       Date:  2008-07       Impact factor: 8.086

10.  Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

Authors:  M Haas; B Sis; L C Racusen; K Solez; D Glotz; R B Colvin; M C R Castro; D S R David; E David-Neto; S M Bagnasco; L C Cendales; L D Cornell; A J Demetris; C B Drachenberg; C F Farver; A B Farris; I W Gibson; E Kraus; H Liapis; A Loupy; V Nickeleit; P Randhawa; E R Rodriguez; D Rush; R N Smith; C D Tan; W D Wallace; M Mengel
Journal:  Am J Transplant       Date:  2014-02       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.